Onco Wiki / Biomarcador

Hormona anti-mülleriana (reserva ovária — temporização do BSO em transportadores BRCA)

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDBIO-AMH-OVARIAN-RESERVE
TipoBiomarcador
Alegais
AMHHormônio Anti-MüllerianMISSubstância inibidora da müllerianaАнтимюллерів гормон (оваріальний резерв — час BSO у носіїв BRCA)
Estadoreviewed 2026-05-18 | pending_clinical_signoff
DoençasDIS-OVARIAN
FontesSRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025

Fatos de biomarcadores

Tipo de biomarcadorserum_marker
Medição
MétodoImunoensaio sérico (ECLIA, CLIA); ciclo-dia independente
Unidadesng/mL (ou pmol/L; conversão 1 ng /mL ‡ 7,14 pmol /L)
Gama típica
  • 0.5
  • 5.0
Biomarcadores relacionadosNenhuma declaração

Notas

Granulosa-cell-derived hormone reflecting primordial follicle pool; best single biomarker of ovarian reserve. Adjunct to risk-reducing bilateral salpingo-oophorectomy (RRSO) counseling in BRCA1/BRCA2 germline carriers and other HBOC syndromes (BRIP1, RAD51C, RAD51D, PALB2). NCCN 2025 (Genetic/Familial High-Risk: Breast/Ovarian): BRCA1 RRSO recommended at age 35-40 (after completion of childbearing); BRCA2 at age 40-45. AMH supports timing discussion — declining AMH (<1.0 ng/mL = diminished reserve) helps quantify remaining reproductive window and informs fertility-preservation referral (oocyte/embryo cryopreservation) before RRSO. NOT a screening test for ovarian cancer (CA-125 + TVUS combination has been evaluated and is NOT recommended for screening per UKCTOCS — no mortality benefit). Used in pediatric ovarian function monitoring after gonadotoxic chemotherapy (childhood cancer survivors). Falsely elevated in granulosa-cell tumors and PCOS; falsely suppressed by hormonal contraceptives. STUB pending two-Co-Lead signoff.

Usado por

Relevância terapêutica